3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Glioblastoma
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Interventions
Temozolomide
52
Radiotherapy
24
Bevacizumab
23
Radiation
10
Magnetic Resonance Spectroscopy
7
Lomustine
7
Carmustine
7
Radiosurgery
6
Surgical Procedures, Operative
5
Irinotecan
5
Aminolevulinic Acid
5
Radiotherapy, Intensity-Modulated
4
Nivolumab
4
Ipilimumab
4
Erlotinib Hydrochloride
4
Cilengitide
4
vocimagene amiretrorepvec
3
vitespin
3
sargramostim
3
poly ICLC
3
pembrolizumab
3
fluoromisonidazole
3
carmustine, poliferprosan 20 drug combination
3
Vorinostat
3
TPI-287
3
O(6)-benzylguanine
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Flucytosine
3
Dynamic Contrast Enhanced Magnetic Resonance Imaging
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Glioblastoma
×
irinotecan sucrosofate
×
Clear all
NCT03119064
2022-12-13
329
Brown University
Phase 1/2
Terminated
12 enrolled
13 charts